FDA grants emergency use authorization for Merck’s Bravecto to treat screwworm in dogs
The U.S. Food and Drug Administration issued an emergency use authorization for Merck’s Bravecto chewable tablets to treat New World screwworm infestations in dogs and puppies. The authorization was given to Intervet, Merck’s U.S. animal‑health unit, and allows the drug to be prescribed by veterinarians. Bravecto, whose active ingredient is fluralaner, is already approved for flea and tick control but carries known neurological side‑effect risks.
Why it matters
The new indication could expand Bravecto’s veterinary market and generate additional sales for Merck’s animal‑health division, although the requirement for prescription use may limit rapid uptake. The FDA’s assessment that benefits outweigh risks may reassure veterinarians and owners in affected regions.
Key facts
- 1The FDA issued the emergency use authorization on 3 November 2026. kelofm.com
- 2The authorization applies to Merck’s Bravecto tablets for treating New World screwworm in dogs and puppies. kelofm.com
- 3The authorization was issued to Intervet, Merck’s U.S. animal‑health unit. kelofm.com
- 4Bravecto’s active ingredient is fluralaner, an isoxazoline class antiparasitic. kelofm.com
- 5The FDA concluded that it is reasonable to believe Bravecto may be effective and that its benefits outweigh its risks for this use. kelofm.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.